Literature DB >> 21113749

Utility of contrast-enhanced ultrasonography for qualitative imaging of atherosclerosis in Watanabe heritable hyperlipidemic rabbits: initial experimental study.

Ayumi Nitta-Seko1, Norihisa Nitta, Masashi Shiomi, Akinaga Sonoda, Shinichi Ota, Keiko Tsuchiya, Masashi Takahashi, Mineko Fujimiya, Murata Kiyoshi.   

Abstract

PURPOSE: Using Watanabe heritable hyperlipidemic (WHHL) rabbits, we investigated the ability of ultrasonography (US) to detect contrast enhancement of atherosclerotic lesions after intravenous injection of a microbubble contrast agent (MB) and confirmed the localization of MB in the lesion by transmission electron microscopy (TEM).
MATERIALS AND METHODS: The abdominal aortic wall of six WHHL rabbits was observed for 20 min after MB delivery. To evaluate contrast enhancement, a region of interest (ROI) was set in the intima-media complex (IMC) and the aortic lumen. The average image brightness of the ROI was recorded as the echogenicity at each time point. Differences at each time point were analyzed by analysis of variance and the t-test. Histological analysis was performed after US observation.
RESULTS: The echogenicity of the IMC was 8.48 ± 3.01 before and 10.96 ± 7.88, 32.42 ± 12.79, 79, 17.73 ± 9.118, and 31.18 ± 13.35, respectively, at 0.5, 2, 5, 10, and 20 min after MB injection. The echogenicity of the vessel lumen was 1.16 ± 1.57, 64.21 ± 11.52, 53.55 9.81, 13.32 ± 9.78, 2.63 ± 1.45, and 3.66 ± 3.01 at the corresponding time points. At 20 min after injection, the echogenicity of the IMC was significantly higher than before or 0.5 min after injection. The distribution of MB inside macrophages in atherosclerotic plaques could not be confirmed by TEM.
CONCLUSION: Ultrasonography was able to detect contrast enhancement of the IMC at 10 and 20 min after injection of MB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21113749     DOI: 10.1007/s11604-010-0487-0

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  33 in total

1.  Ultrasmall superparamagnetic iron oxide-enhanced MR imaging of atherosclerotic plaque in hyperlipidemic rabbits.

Authors:  Stefan G Ruehm; Claire Corot; Peter Vogt; Heidi Cristina; Jörg F Debatin
Journal:  Acad Radiol       Date:  2002-05       Impact factor: 3.173

2.  Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits.

Authors:  Jingyan Liang; Enqi Liu; Ying Yu; Shuji Kitajima; Tomonari Koike; Yingji Jin; Masatoshi Morimoto; Kinta Hatakeyama; Yujiro Asada; Teruo Watanabe; Yasuyuki Sasaguri; Shigeyuki Watanabe; Jianglin Fan
Journal:  Circulation       Date:  2006-04-25       Impact factor: 29.690

3.  Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells.

Authors:  Kyosuke Yanagisawa; Fuminori Moriyasu; Takeo Miyahara; Miyata Yuki; Hiroko Iijima
Journal:  Ultrasound Med Biol       Date:  2007-02       Impact factor: 2.998

4.  Contrast-enhanced ultrasound imaging of intraplaque neovascularization in carotid arteries: correlation with histology and plaque echogenicity.

Authors:  Stefano Coli; Marco Magnoni; Giuseppe Sangiorgi; Massimiliano M Marrocco-Trischitta; Giulio Melisurgo; Alessandro Mauriello; Luigi Spagnoli; Roberto Chiesa; Domenico Cianflone; Attilio Maseri
Journal:  J Am Coll Cardiol       Date:  2008-07-15       Impact factor: 24.094

5.  Characterization of tumor imaging with microbubble-based ultrasound contrast agent, sonazoid, in rabbit liver.

Authors:  Rira Watanabe; Manabu Matsumura; Chun-Jen Chen; Yuki Kaneda; Masayoshi Fujimaki
Journal:  Biol Pharm Bull       Date:  2005-06       Impact factor: 2.233

6.  Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary plaque-prone WHHL rabbits.

Authors:  Masashi Shiomi; Satoshi Yamada; Takashi Ito
Journal:  Atherosclerosis       Date:  2005-02       Impact factor: 5.162

7.  (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials.

Authors:  James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Ash Rafique; Michael Farkouh; Valentin Fuster; Zahi A Fayad
Journal:  J Am Coll Cardiol       Date:  2007-08-13       Impact factor: 24.094

8.  Detection of atherosclerotic plaque with Gadofluorine-enhanced magnetic resonance imaging.

Authors:  Jörg Barkhausen; Wolfgang Ebert; Claudia Heyer; Jörg F Debatin; Hanns-Joachim Weinmann
Journal:  Circulation       Date:  2003-06-30       Impact factor: 29.690

Review 9.  Imaging of atherosclerotic cardiovascular disease.

Authors:  Javier Sanz; Zahi A Fayad
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

10.  Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid.

Authors:  Kinuyo Hatanaka; Masatoshi Kudo; Yasunori Minami; Taisuke Ueda; Chie Tatsumi; Satoshi Kitai; Shunsuke Takahashi; Tatsuo Inoue; Satoru Hagiwara; Hobyung Chung; Kazuomi Ueshima; Kiyoshi Maekawa
Journal:  Intervirology       Date:  2008-06-10       Impact factor: 1.763

View more
  3 in total

1.  Optical Verification of Microbubble Response to Acoustic Radiation Force in Large Vessels With In Vivo Results.

Authors:  Shiying Wang; Claudia Y Wang; Sunil Unnikrishnan; Alexander L Klibanov; John A Hossack; F William Mauldin
Journal:  Invest Radiol       Date:  2015-11       Impact factor: 6.016

2.  Binding dynamics of targeted microbubbles in response to modulated acoustic radiation force.

Authors:  Shiying Wang; John A Hossack; Alexander L Klibanov; F William Mauldin
Journal:  Phys Med Biol       Date:  2013-12-30       Impact factor: 3.609

Review 3.  Cardiovascular imaging: what have we learned from animal models?

Authors:  Arnoldo Santos; Leticia Fernández-Friera; María Villalba; Beatriz López-Melgar; Samuel España; Jesús Mateo; Ruben A Mota; Jesús Jiménez-Borreguero; Jesús Ruiz-Cabello
Journal:  Front Pharmacol       Date:  2015-10-21       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.